Application of FGL1 protein in preparation of kit for diagnosing vertigo

Abstract

The invention discloses application of FGL1 protein in preparation of a kit for diagnosing vertigo. Clinically, diagnosis of vertigo depends on diagnosis experience of doctors, complaint of patients becomes a main diagnosis basis, the doctors perform preliminary diagnosis according to physical examination, medical history inquiry and the like and then perform clear diagnosis according to etiological examination, diagnosis time is long, and preliminary diagnosis subjectivity is high. It is found that the FGL1 protein can effectively diagnose and distinguish healthy subjects and patients with vertigo, the diagnosis accuracy is high, the FGL1 protein can be used for being developed into a kit for diagnosing vertigo, and compared with an existing diagnosis method, the diagnosis efficiency and objectivity are obviously improved.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of disease diagnosis, and relates to discovery and application of a disease diagnosis marker, in particular to use of FGL1 protein for preparing a kit for diagnosing vertigo. BACKGROUND

[0002] Vertigo is a common clinical symptom. Foreign epidemiological studies show that the lifetime prevalence of vertigo in adults aged 18-79 is 7.4%, the annual prevalence is 4.9%, and the annual incidence is 1.4%. Clinically, the diagnosis of vertigo is more dependent on the diagnosis experience of doctors, and the patient's complaint becomes the main basis for diagnosis. Doctors make a preliminary diagnosis according to physical examination and medical history inquiry, and then make a definite diagnosis according to etiological examination. The diagnosis is time-consuming and subjective.

[0003] There is no report on use of fibrinogen-related protein 1 (FGL1) for diagnosing vertigo.

[0004] In order to improve the diagnosis efficiency and objectivity of vertigo, the present application is proposed. SUMMARY

[0005] The present application aims to overcome the shortcomings of the prior art, and provides use of FGL1 protein for preparing a kit for diagnosing vertigo.

[0006] The above object of the present application is achieved by the following technical scheme:

[0007] Use of FGL1 protein for preparing a kit for diagnosing vertigo.

[0008] Preferably, the kit is a serum detection kit.

[0009] Preferably, the kit contains a detection reagent of FGL1 protein.

[0010] Beneficial effects:

[0011] The present application finds that the content of FGL1 protein in the serum of healthy subjects and vertigo patients is significantly different, and the content of FGL1 protein in the serum of vertigo patients is significantly lower than that of healthy subjects. Further diagnostic efficiency test shows that FGL1 protein can effectively diagnose and distinguish healthy subjects from vertigo patients, has high diagnostic accuracy, and can be used for developing a kit for diagnosing vertigo, which significantly improves the diagnostic efficiency and objectivity of the existing diagnosis method. BRIEF DESCRIPTION OF DRAWINGS

[0012] Figure 1 ROC curve of FGL1 protein for diagnosing and distinguishing healthy subjects from vertigo patients in the training set;

[0013] Figure 2 To validate the sample distribution map of healthy subjects vs. patients with vertigo based on FGL1 protein prediction in the set. Detailed Implementation

[0014] The substantive content of the present invention will be described in detail below with reference to the accompanying drawings and embodiments, but this is not intended to limit the scope of protection of the present invention.

[0015] I. Experimental Samples and Reagents

[0016] Forty healthy subjects and forty patients with vertigo were enrolled. Healthy subjects were identified as normal individuals who underwent a physical examination, and patients with vertigo were diagnosed according to the Guidelines for the Emergency Diagnosis and Treatment of Vertigo (2021). Patients in each group were matched for age, sex, and body mass index, with no significant differences. Subjects or patients in each group were randomly assigned to either a training set (20 healthy subjects and 20 patients with vertigo) or a validation set (20 healthy subjects and 20 patients with vertigo).

[0017] Exclusion criteria:

[0018] ① Individuals with other acute or uncontrolled chronic diseases; ② Individuals with serious primary diseases of the cardiovascular, cerebrovascular, liver, kidney, and hematopoietic systems; ③ Individuals with mental illness who are unable to cooperate; ④ Pregnant or lactating women, or those planning to become pregnant; ⑤ Individuals who have participated in other clinical trials within the past month; ⑥ Individuals who do not wish to participate in this study.

[0019] Main experimental reagents:

[0020] The ELISA reagent for measuring FGL1 protein was purchased from Ray Biotech, Inc.

[0021] II. Experimental Methods

[0022] 1. Collection and storage of serum samples

[0023] Fasting peripheral blood was collected from healthy subjects and patients with vertigo in the morning and placed in test tubes without anticoagulants. The blood was allowed to coagulate naturally at room temperature for 30-60 minutes. After the blood had coagulated, it was centrifuged at 2000 rpm for 10 minutes. The clear serum liquid at the top was carefully aspirated into sterile lyophilized tubes, labeled, and stored at -80°C for later use.

[0024] 2. ELISA to determine the level of FGL1 protein in serum.

[0025] The content of FGL1 protein in each serum sample was determined strictly according to the ELISA reagent test instructions.

[0026] 3. Data processing methods

[0027] ROC curves were established to differentiate healthy subjects from vertigo patients using FGL1 protein in the test set. The area under the curve (AUC) and 95% confidence interval were calculated. Logistic regression was used to establish a regression equation, generating a new variable logit[P]. The expression logit[P] = Ln... [p / (1-p)] The transformation yields the predicted probability p, and ROC curve analysis is performed on this new variable. In the validation set, the diagnostic accuracy of FGL1 protein for vertigo is calculated using the optimal cut-off value obtained from the ROC curve as the threshold.

[0028] III. Experimental Results

[0029] 1. Differences in serum levels of FGL1 protein between healthy subjects and patients with vertigo.

[0030] In the training set, there were significant differences in the serum levels of FGL1 protein between healthy subjects and patients with vertigo. The absolute level of FGL1 in the serum of patients with vertigo was significantly downregulated. The results are shown in the table below.

[0031] Group FGL1 content (ng / mL) Vertigo patients 15.15±7.70 Healthy subjects 44.84±39.88

[0032] 2. ROC curve for FGL1 protein diagnosis distinguishing healthy subjects from patients with vertigo.

[0033] Using the FGL1 protein content (X) in the training set as the independent variable and the group (i.e., healthy subjects and vertigo patients) as the dependent variable, logistic regression was performed on the FGL1 protein content in serum samples from vertigo patients and healthy subjects, yielding the logistic regression equation: Ln [p / (1-p)] = -0.15X + 3.52; Substituting the absolute content of FGL1 protein in each serum sample into the logistic regression equation, the regression prediction probability p of each serum sample can be obtained. Using the possible regression prediction probability p as the diagnostic point, sensitivity and specificity are calculated, and an ROC curve is plotted accordingly (e.g., Figure 1 As shown in the figure, the AUC was 0.875, the sensitivity was 1, and the specificity was 0.70. The Wieden index was calculated based on the ROC curve coordinates as: specificity + sensitivity - 1. The predicted probability p-value corresponding to the maximum Wieden index was the optimal cut-off value of 0.39 for classifying healthy subjects versus vertigo patients for diagnostic purposes.

[0034] The area under the ROC curve (AUC) is widely recognized as an inherent accuracy indicator for evaluating the validity of diagnostic tests. An AUC of 0.5 indicates no diagnostic significance; an AUC between 0.5 and 0.7 indicates low diagnostic accuracy; an AUC between 0.7 and 0.9 indicates moderate diagnostic accuracy; and an AUC greater than 0.9 indicates high diagnostic accuracy.

[0035] 3. Verify the accuracy of FGL1 protein in diagnosing vertigo.

[0036] In the validation set, serum samples from patients with vertigo versus healthy subjects were predicted using the optimal cut-off value obtained above as the diagnostic threshold. The accuracy of FGL1 protein in distinguishing between patients with vertigo and healthy subjects was calculated by dividing the number of correctly predicted samples by the total number of samples. The accuracy of FGL1 protein in distinguishing between patients with vertigo and healthy subjects was 80.00% (32 / 40). The sample distribution is shown in the figure below. Figure 2 As shown.

[0037] In summary, the FGL1 protein can effectively differentiate between healthy subjects and patients with vertigo, with a high diagnostic accuracy. It can be used to develop a diagnostic kit for vertigo, which significantly improves diagnostic efficiency and objectivity compared to existing diagnostic methods.

[0038] The purpose of the above embodiments is to specifically illustrate the substantive content of the present invention, but those skilled in the art should know that the scope of protection of the present invention should not be limited to the specific embodiments.

Claims

1. The use of an FGL1 protein in the preparation of a kit for diagnosing vertigo.

2. According to claim 1, the kit is a serum detection kit.

3. The use according to claim 1, wherein the kit contains a detection reagent for FGL1 protein.

Images